180 Life Sciences Corp.
ATNF
$0.8599
-$0.0011-0.13%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -4.27M | -836.70K | 11.80K | -1.07M | -1.23M |
| Total Depreciation and Amortization | -3.10K | 13.90K | 24.00K | 23.60K | 22.70K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.82M | -20.80K | -134.90K | 236.30K | 519.80K |
| Change in Net Operating Assets | 509.80K | 620.00K | 826.30K | -223.50K | -1.48M |
| Cash from Operations | -950.70K | -223.70K | 727.20K | -1.03M | -2.16M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | 969.30K |
| Total Debt Repaid | -327.60K | -476.10K | -264.90K | -264.90K | -272.20K |
| Issuance of Common Stock | 5.37M | 0.00 | 0.00 | 500.00 | 831.10K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -59.80K |
| Cash from Financing | 5.04M | -476.10K | -264.90K | -264.40K | 1.47M |
| Foreign Exchange rate Adjustments | 297.80K | -251.60K | 8.00K | -2.00K | 4.90K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4.39M | -951.40K | 470.30K | -1.30M | -686.70K |